A review of current treatment options in multiple myeloma is presented, including data on health-related quality of life and pharmacoeconomics. For induction chemotherapy, no combination of cytostatic drugs has been shown to be consistently superior to the simple cyclic oral treatment with...

In order to avoid undue discrimination of disabled people, we have suggested that all life years gained by the disabled should count as 1 in QALY calculations as long as the health states in question are preferred to being dead by those concerned. Johannesson noted that such a convention could...

In an earlier article in Health Economics, Salomon and Murray argue that by applying maximum likelihood techniques to predetermined functional forms and to a data set where a number of health states are valued by means of four standard valuation techniques, underlying 'pure' valuations of health...

The paper addresses some limitations of the QALY approach and outlines a valuation procedure that may overcome these limitations. In particular, we focus on the following issues: the distinction between assessing individual utility and assessing societal value of health care; the need to...

The desirability of a condition to people who are not in it themselves is only moderately correlated to the experienced well being of people with the condition and hardly correlated at all to the worth of those people. A single score for a health state, of the kind used in QALY calculations,...

No Abstract

Background: The person trade-off (PTO) is a technique for eliciting preferences for resource allocation across patient groups. In principle PTO responses should satisfy a requirement of multiplicative transitivity, i.e. that if people consider treatment of 1 in state A to be equivalent to...